Evidence map›Paper›PMID 38784824›Full record

ReviewEnvironmental sciences Europe2024

Grouping strategies for assessing and managing persistent and mobile substances.

Parviel Chirsir, Emma H Palm, Sivani Baskaran, Emma L Schymanski, Zhanyun Wang, Raoul Wolf, Sarah E Hale, Hans Peter H Arp

Abstract readReview
In one paragraph

Review in Environmental sciences Europe, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Parviel ChirsirLuxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, 6 Avenue du Swing, 4367 Belvaux, Luxembourg.ORCID 0000-0002-9932-8609
Emma H PalmLuxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, 6 Avenue du Swing, 4367 Belvaux, Luxembourg.ORCID 0000-0001-7774-2510
Sivani BaskaranDepartment of Environmental Engineering, Norwegian Geotechnical Institute, 0806 Oslo, Norway.ORCID 0000-0001-6192-5072
Emma L SchymanskiLuxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, 6 Avenue du Swing, 4367 Belvaux, Luxembourg.ORCID 0000-0001-6868-8145
Zhanyun WangTechnology and Society Laboratory, Empa-Swiss Federal Laboratories for Materials Science and Technology, 9014 St. Gallen, Switzerland.ORCID 0000-0001-9914-7659
Raoul WolfDepartment of Environmental Engineering, Norwegian Geotechnical Institute, 0806 Oslo, Norway.ORCID 0000-0001-5971-8525
Sarah E HaleTZW: DVGW-Technologiezentrum Wasser (German Water Centre), Karlsruher Straße 84, 76139 Karlsruhe, Germany.ORCID 0000-0002-7743-9199
Hans Peter H ArpDepartment of Environmental Engineering, Norwegian Geotechnical Institute, 0806 Oslo, Norway.ORCID 0000-0002-0747-8838

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Persistent, mobile and toxic (PMT), or very persistent and very mobile (vPvM) substances are a wide class of chemicals that are recalcitrant to degradation, easily transported, and potentially harmful to humans and the environment. Due to their persistence and mobility, these substances are often widespread in the environment once emitted, particularly in water resources, causing increased challenges during water treatment processes. Some PMT/vPvM substances such as GenX and perfluorobutane sulfonic acid have been identified as substances of very high concern (SVHCs) under the European Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) regulation. With hundreds to thousands of potential PMT/vPvM substances yet to be assessed and managed, effective and efficient approaches that avoid a case-by-case assessment and prevent regrettable substitution are necessary to achieve the European Union's zero-pollution goal for a non-toxic environment by 2050. Main: Substance grouping has helped global regulation of some highly hazardous chemicals, e.g., through the Montreal Protocol and the Stockholm Convention. This article explores the potential of grouping strategies for identifying, assessing and managing PMT/vPvM substances. The aim is to facilitate early identification of lesser-known or new substances that potentially meet PMT/vPvM criteria, prompt additional testing, avoid regrettable use or substitution, and integrate into existing risk management strategies. Thus, this article provides an overview of PMT/vPvM substances and reviews the definition of PMT/vPvM criteria and various lists of PMT/vPvM substances available. It covers the current definition of groups, compares the use of substance grouping for hazard assessment and regulation, and discusses the advantages and disadvantages of grouping substances for regulation. The article then explores strategies for grouping PMT/vPvM substances, including read-across, structural similarity and commonly retained moieties, as well as the potential application of these strategies using cheminformatics to predict P, M and T properties for selected examples. Conclusions: Effective substance grouping can accelerate the assessment and management of PMT/vPvM substances, especially for substances that lack information. Advances to read-across methods and cheminformatics tools are needed to support efficient and effective chemical management, preventing broad entry of hazardous chemicals into the global market and favouring safer and more sustainable alternatives.

Indexed as

Chemical regulationHazardous propertiesMobilePersistentPMTRegrettable substitutionSubstance groupingToxicTransformation productsvPvM

Identifiers

PMID38784824
PMCPMC11108893

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.